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We recently celebrated the first anniversary of our partnership 
with Elsevier. Among the many benefits from our collaboration, 
we recognize the change in our article submission system, by 
shifting to the Elsevier Editorial System (EES). An easy-to-use 
system, EES provides us with access to advantages not offered 
by our previous systems.
First, EES allows us to use Technical Check in order to return 
poorly prepared manuscripts to their authors for revision, as 
well as manuscripts that do not meet the established criteria. 
As a result, we have reduced the number of direct rejections 
due to formatting reasons. Second, we now have access to a 
search engine of reviewers worldwide. With a few keywords, 
we can access dozens of researchers with expertise in the 
specialized area of any submitted manuscript. Though many 
do not accept to review—a problem common to all journals—
we have generally been more successful in finding qualified 
scholars to review our manuscripts. Third, we now enjoy 
CrossCheck, which uses iThenticate software to identify 
similarities between texts in order to detect plagiarism. Fourth, 
EES allows us to participate in its Article Transfer Service, 
which facilitates the automatic transfer of manuscripts among 
journals in the same field. Fifth and finally, our partnership 
with Elsevier improves the visibility of our authors’ accepted 
papers, which are now available online in open access via two 
important portals: SciELO Brasil and ScienceDirect. 
Nevertheless, we remain unable to enjoy all of the features 
that our partnership offers. For example, we still cannot 
provide Elsevier with a sufficient number of articles to have 
in ahead of print, nor can we use the Graphical Abstract and 
other tools available. We are currently in the process of fully 
professionalizing our journal, and as such, we still have much 
work ahead of us.
We should acknowledge that our partnership with Elsevier 
establishes a new way of working with BJP, envisions new 
horizons for the journal, and allows us to forecast robust 
growth in the coming years. However, these improvements 
in quality—in graphics and in content, in more flexible 
assessment, and in publishing with XML, among others—
come at a cost. Today, the price tag for each article is about 
$620. Yet, this cost is low compared to that of other journals 
publishing articles with open access. Unfortunately, we 
cannot afford the full cost with only what we have received 
from the publishing program at CNPq/CAPES/MCT. We must 
request that authors pay a fee, which is used to pay the costs 
of technical editing, preparing manuscripts for publication on 
the website, printing, and electronic distribution, to name a 
few. The remaining funds needed come from the Brazilian 
Society of Pharmacognosy.
In retrospect of our year with Elsevier, we recognize that 
our relocation was the most appropriate way to meet the goals 
set for the journal five years ago: to give Brazilian researchers 
the opportunity to have their work published in a journal 
with greater visibility, as well as to access top international 
journals—both of which are quite difficult to achieve. BJP 
is thus working hard to fulfill its mission to increase the 
publication of pharmacognostic and natural product research 
conducted in Brazil. 
Ultimately, we rely heavily on encouragement from our 
readers, researchers, lecturers, and students in supporting 
our work. You can help us to better fulfill our mission in two 
fundamental ways: by submitting manuscripts for publication 
and by reviewing manuscripts. With this help, we can celebrate 
our successful partnership with three united forces: our 
researchers and authors, our editors, and our publisher.
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